mRNA Pancreatic Cancer Vaccine Trial Shows Long-Term Survival in Responders
“Of 16 patients in Balachandran’s trial, eight showed a dramatic immune response to the mRNA-based vaccine. Seven of the eight are alive and well six years after the trial began, a finding that was to be presented Monday at the American Association of Cancer Research meeting in San Diego.”
New data from a clinical trial led by Dr. Vinod Balachandran at Memorial Sloan Kettering Cancer Center (MSK) indicates that an experimental mRNA-based vaccine for pancreatic cancer has produced lasting immune responses. Of the 16 patients in the trial, eight developed a strong immune response, and seven of those eight remain alive and well six years later. These findings were...